Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Iovance Biotherapeutics ( (IOVA) ) just unveiled an update.
On March 17, 2026, Iovance Biotherapeutics announced that board member Wendy Yarno will retire from its Board of Directors and will not stand for re-election at the company’s annual meeting of stockholders expected in June 2026. Yarno will continue to serve as a director until the annual meeting, and the company emphasized that her decision was not related to any disagreement over Iovance’s operations, policies, or practices, while publicly thanking her for her service to the board.
The planned retirement signals an upcoming change in Iovance’s board composition later in 2026, though the company indicated a stable governance environment by clarifying there were no underlying disputes driving the decision. Stakeholders are likely to view the transition as an orderly refresh of board membership rather than a sign of internal conflict or strategic upheaval.
The most recent analyst rating on (IOVA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.
Spark’s Take on IOVA Stock
According to Spark, TipRanks’ AI Analyst, IOVA is a Neutral.
Overall score reflects strong technical momentum and a positive earnings-call backdrop around accelerating product revenue and improving margins, partially offset by weak underlying financial performance driven by large losses and continued cash burn. Valuation is constrained by negative earnings (negative P/E) and no dividend yield data.
To see Spark’s full report on IOVA stock, click here.
More about Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. is a biotechnology company focused on developing and commercializing novel cancer immunotherapies. Its work centers on advancing innovative treatments for oncology patients, positioning the company within the rapidly evolving immuno-oncology market.
Average Trading Volume: 15,035,060
Technical Sentiment Signal: Hold
Current Market Cap: $1.59B
For detailed information about IOVA stock, go to TipRanks’ Stock Analysis page.